Skin And Cancer Associates Llp

CLIA Laboratory Citation Details

3
Total Citations
11
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 10D1103654
Address 2925 Ne 199 Street, Ste 205, Aventura, FL, 33180
City Aventura
State FL
Zip Code33180
Phone(305) 933-6716

Citation History (3 surveys)

Survey - July 11, 2025

Survey Type: Standard

Survey Event ID: T0VM11

Deficiency Tags: D5400 D0000 D5417

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at SKIN AND CANCER ASSOCIATES LLP from 07/02/2025 to 07/11/2025. The laboratory was not in compliance with 42 CFR Part 493, Requirement for Laboratories. The following Condition was cited: D5400 CFR 493.1250 Condition: Analytic Systems. D5400 ANALYTIC SYSTEMS CFR(s): 493.1250 Each laboratory that performs nonwaived testing must meet the applicable analytic systems requirements in 493.1251 through 493.1283, unless HHS approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub.7), that provides equivalent quality testing. The laboratory must monitor and evaluate the overall quality of the analytic systems and correct identified problems as specified in 493.1289 for each specialty and subspecialty of testing performed. This CONDITION is not met as evidenced by: Based on observation, record review and Staff interview, the Laboratory failed to stop using expired reagents in Histopathology testing. Refer to D5417. D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) (d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on observation, record review and staff interview, the laboratory used expired reagent in use: 1 bottle of Eosin Y Stain Solution, 1 % expired on 02/21/2025 and 2 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- bottles of Hematoxylin Solution Gill III one expired on 03/13/2024 and the second one expired on 05/25/2025, both solutions used for the Hematoxylin and Eosin (H&E) stain. This is a repeated deficiency from the recertification survey completed on 11/06 /2023. Findings Included: 1-During laboratory tour on 07/02/2025 at 10:30 AM, the surveyor found in the fire safety cabinet the following expired reagents: 1 liter bottle with approximately 800 ml of Eosin Y Stain Solution 1 %, lot number 2304107 expired since 02/21/2025 and labeled as Waste, two one-liter bottles of Hematoxylin Solution Gill III, also marked as Waste, one with Lot number 2206912 expired on 03 /13/2024 and the volume left was approximately 100 ml and the second bottle was unopened with lot number 2311814 expired on 05/25/2025. 2-Review of reagent log for 2023, 2024 and 2025, revealed that the reagents registered matched the ones found in the fire cabinet. The laboratory had no other record of Eosin and Hematoxylin solutions. 3-Patient log review revealed that the laboratory performed H&E stain in the following dates: 03/04/2025 (9 patients), 03/05/2025 (7 patients), 03/21/2025 (5 patients), 04/25/2025 (14 patients), 05/30/2025 (6 patients), 06/20/2025 (11 patients) for a total of 52 patients that were tested using expired reagents. 4-During an interview on 07/02/2025 at 10:40 am with the Laboratory Consultant, she confirmed that the laboratory used the expired reagents listed above and they notified the office, no purchase documentation was available. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - November 6, 2023

Survey Type: Standard

Survey Event ID: 9NBL11

Deficiency Tags: D5417 D5473 D0000 D5433 D6120

Summary:

Summary Statement of Deficiencies D0000 A recertification survey conducted on 11/06/2023 found the SKIN AND CANCER ASSOCIATES LLP clinical laboratory not in compliance with 42 CFR Part 493, Requirements for Laboratories. D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on observation, record review and interview, the laboratory failed to stop using the following expired reagents: Tissue Freezing Medium and the Liquimount from 01 /01/2022 to present. Findings included: During laboratory tour on 11/06/2023 at 10:00 AM, the surveyor found that the laboratory had the following expired reagents in use: - One open bottle and four unopened bottles of Mercedes Scientific Tissue Freezing Medium with Lot 85814 expired since 07/2021. There were no records of the reception and date of initial use of this reagent in the reagent log. - One open bottle of Mercedes Scientific Liquimount cover slipping with Lot 114845 and expired since 01 /31/2023. -The laboratory tested 197 patients using the expired reagents since 01/01 /2022 to present. -Review of the Quality Control policy from procedure Manual signed by the Laboratory Director on 09/15/2023 revealed that expired reagents will be disposed properly. During an interview on 11/06/2023 at 11:00 AM, the Office Assistant confirmed that the laboratory used the expired reagents for the period of reference. D5433 MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(b)(1) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- For equipment, instruments, or test systems developed in-house, commercially available and modified by the laboratory, or maintenance and function check protocols are not provided by the manufacturer, the laboratory must establish a maintenance protocol that ensures equipment, instrument, and test system performance that is necessary for accurate and reliable test results and test result reporting. The laboratory must perform and document the maintenance activities specified in paragraph (b)(1)(i) of this section. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to document all maintenance activities for 2 out of 26 testing days since 01/01/2022 to present. Findings included: Review of Patient Log for 2022 and 2023 revealed that the laboratory tested 11 patients on 10/07/2022 and 8 patients on 01/13/2023. The laboratory document "H + E Stainer Log", did not have documentation showing the Hematoxylin and Eosin (H&E) stain used was Added, Rotated Up, Filtered or Changed on 10/07/2022 and on 01/13/2023. Review of Logs: Mohs Quality Control for 2022 and Mohs Laboratory Quality Control for 2023, revealed that the laboratory failed to document Daily Cryostat Maintenance on 10/07/2022 and 01/13/2023. During an interview on 11/06/2023 at 11:30 AM, the Office Assistant confirmed that the laboratory failed to have documentation of the daily maintenance of the H&E stain and Cryostat for the days of reference. D5473 CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on record review and interview, the laboratory failed to have documentation of the acceptability of the Quality Control (QC) slide for Hematoxylin & Eosin (H&E) stain for 2 out of 26 testing dates from 01/01/2022 to present. Findings included: The laboratory used the "Quality Control Slide" Log in 2022 and the "Quality Control Staining" Log for 2023 to record the acceptability of the H&E stain. Review of the QC logs revealed that the laboratory had no documentation of the acceptability of the QC slides for 10/07/2022 (11 patients tested) and for 01/13/2023 (8 patients tested) During an interview on 11/06/2023 at 11:30 AM the Office Assistant confirmed that the laboratory failed to document the acceptability of the Daily QC slide for H&E stain on the days listed above. D6120 TECHNICAL SUPERVISOR RESPONSIBILITIES CFR(s): 493.1451(b)(7)(8) (7) The technical supervisor is responsible for identifying training needs and assuring that each individual performing tests receives regular in-service training and education appropriate for the type and complexity of the laboratory services performed; (8) Evaluating the competency of all testing personnel and assuring that the staff maintain their competency to perform test procedures and report test results promptly, -- 2 of 3 -- accurately and proficiently. This STANDARD is not met as evidenced by: Based on record review and interview, the Technical Supervisor (TS) failed to evaluate the competency for five out of five testing personnel (TP) for the two years reviewed. Findings included: -Review of the FORM CMS-209 signed by the Laboratory Director (LD) on 11/03/2023 revealed that the LD, Clinical Consultant (CC), TS, General Supervisor (GS) was also TP#A. The laboratory had five TP (TP#A, TP#B, TP#C, TP#D and TP#E). -Review of personnel records revealed that there were no competencies evaluations performed during 2022 and 2023. During an interview on 11/06/2023 at 11:35 AM with Office Asistant, she confirmed that the TS failed to perform the competencies listed above. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - November 20, 2019

Survey Type: Standard

Survey Event ID: ZRCI11

Deficiency Tags: D3011 D0000 D5217

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Skin and Cancer Associates LLP on 11/20/19. The laboratory is not in compliance with 42 CFR Part 493, Requirements for Laboratories. The following is a description of the standard level deficiencies: D3011 FACILITIES CFR(s): 493.1101(d) Safety procedures must be established, accessible, and observed to ensure protection from physical, chemical, biochemical, and electrical hazards, and biohazardous materials. This STANDARD is not met as evidenced by: Based on observations and interview with the Risk Manager the laboratory failed to dispose of alcohol, xylene substitute, and eosin reagents per the manufacturers' instructions for at least 2 (2017-2019) out of 2 years reviewed. Findings Included: During a tour of the laboratory on 11/20/19 at 10:30 AM it was observed alcohol, xylene substitute, and eosin in the flammable cabinet. No chemical waste container was observed. Interview with the Risk Manager on 11/20/19 at 10:30 AM revealed that the chemicals were dumped down the drain in the sink for disposal. Review of the label on the bottle of all 3 chemicals revealed that the manufacturers' instructions state "Dispose of contents/container to an approved waste disposal plant." D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on record review and interview with the Risk Manager the laboratory failed to verify the accuracy of testing of Histopathology for 1 (2018) out of 2 years (2018- 2019) reviewed. Findings Included: Review of the policy for "MOHS Proficiency Testing" revealed that "Semi-annually, 2 cased will be randomly selected by the histotechnologist and will be submitted to a Board-Certified Dermatopathologist /Dermatologist for review." Review of the peer review revealed that in 2018 it was only done on 12/24/18. Interview on 11/20/19 at 11:00 AM the Risk Manager confirmed that the peer review was only done once in 2018. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access